BIOMARIN PHARMACEUTICAL INC Derivative Liability, Fair Value, Gross Liability
BIOMARIN PHARMACEUTICAL INC (BMRN) had Derivative Liability, Fair Value, Gross Liability of $41.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Offsetting
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2026-08-06
- 2026-06-30: Derivative Liability, Fair Value, Gross Liability $41.08M.
- 2026-03-31: Derivative Liability, Fair Value, Gross Liability $38.58M.
- 2025-12-31: Derivative Liability, Fair Value, Gross Liability $40.91M.
- 2025-09-30: Derivative Liability, Fair Value, Gross Liability $58.54M.
| Period end | Derivative Liability, Fair Value, Gross Liability | Derivative Liability, Fair Value, Gross Liability as first filed |
|---|---|---|
| 2026-06-30 | $41.08M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $38.58M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $40.91M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $58.54M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $72.00M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $16.66M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $15.59M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $19.62M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $8.94M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $16.19M 10-Q · filed 2024-04-26 | |
| 2023-12-31 | $42.02M 10-K · filed 2025-02-24 | |
| 2023-09-30 | $14.21M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $24.82M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $18.10M 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $13.68M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $15.30M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $12.07M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $15.70M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $7.64M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $6.81M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $13.93M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $12.01M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $28.82M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $12.18M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $11.85M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $13.46M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $15.94M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $16.37M 10-Q/A · filed 2019-11-04 | |
| 2019-06-30 | $11.41M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $12.35M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $7.83M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $10.51M 10-Q · filed 2018-10-26 | |
| 2018-06-30 | $11.74M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $35.49M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $27.15M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $25.81M 10-Q · filed 2017-10-31 | |
| 2017-06-30 | $16.00M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $8.72M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $7.54M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $5.33M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $5.94M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $11.00M 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $5.07M 10-Q · filed 2016-11-03 | |
| 2015-09-30 | $5.82M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $5.14M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $805.00K 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $5.07M 10-K · filed 2017-02-27 | $12.00K 10-K · filed 2015-03-02 |
| 2013-12-31 | $2.19M 10-K · filed 2015-03-02 | |
| 2012-03-31 | $791.00K 10-Q · filed 2012-04-30 | |
| 2011-12-31 | $220.00K 10-Q · filed 2012-04-30 | |
| 2011-09-30 | $926.00K 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $6.26M 10-Q · filed 2011-08-01 | |
| 2010-12-31 | $1.67M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |